List of articles in "Drug" category - Page 118

PRX-07034 is a selective 5-HT6 receptor antagonist. It has cognition and memory-enhancing properties and potently decreases food intake and body weight in rodents. PRX-07034 was under development by Epix Pharmaceuticals […]

SB-742457 is a selective 5-HT6 receptor antagonist with cognition memory and learning-enhancing effects. It is currently under development by GlaxoSmithKline for the treatment of Alzheimer’s disease and has demonstrated preliminary […]

SL65.0155 is a selective 5-HT4 receptor partial agonist (Ki = 0.6 nM; IA = 40-50% (relative to 5-HT)). It potently enhances cognition learning and memory and also possesses antidepressant effects. […]

Lu AE58054 is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer’s disease and schizophrenia. […]

Tedatioxetine (Lu AA24530) is an antidepressant currently under development by Lundbeck and Takeda for the treatment of major depressive disorder (MDD). Tedatioxetine is reported to act as a triple reuptake […]

Pardoprunox (SLV-308) is an antiparkinsonian drug currently under development by Solvay for the treatment of Parkinson’s disease and as of March 2010 is in Phase III clinical trials. It was […]

Vabicaserin (SCA-136) was a novel antipsychotic and anorectic under development by Wyeth. As of 2010 it is no longer in clinical trials for the treatment of psychosis. It was also […]

Eterobarb (Antilon) is a barbiturate derivative. It has mainly anticonvulsant action with less sedative effects than the closely related compound phenobarbital. It saw reasonable success in clinical trials but is […]

Esreboxetine is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available […]